Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 9403754, 13 pages
https://doi.org/10.1155/2017/9403754
Research Article

Global Autorecognition and Activation of Complement by Mannan-Binding Lectin in a Mouse Model of Type 1 Diabetes

1Department of Biomedicine, Wilhelm Meyer’s Allé 4, Faculty of Health Sciences, Aarhus University, Aarhus C, Denmark
2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
3The Danish Diabetes Academy, Odense, Denmark

Correspondence should be addressed to Esben Axelgaard; kd.ua.demoib@xanebse

Received 19 January 2017; Revised 24 March 2017; Accepted 10 April 2017; Published 13 June 2017

Academic Editor: Anna Caretti

Copyright © 2017 Esben Axelgaard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, Global Status Report on Noncommunacable Diseases 2014, World Health Organization, 2015, http://www.who.int/nmh/publications/ncd-status-report-2014/en/.
  2. C. Rask-Madsen and G. L. King, “Vascular complications of diabetes: mechanisms of injury and protective factors,” Cell Metabolism, vol. 17, no. 1, pp. 20–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. W. T. Cade, “Diabetes-related microvascular and macrovascular diseases in the physical therapy setting,” Physical Therapy, vol. 88, no. 11, pp. 1322–1335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Jakuš and N. Rietbrock, “Advanced glycation end-products and the progress of diabetic vascular complications,” Physiological Research, vol. 53, no. 2, pp. 131–142, 2004. View at Google Scholar
  5. M. A. Atkinson, G. S. Eisenbarth, and A. W. Michels, “Type 1 diabetes,” The Lancet, vol. 383, no. 9911, pp. 69–82, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. T. K. Hansen, T. K. Hansen, L. Tarnow et al., “Association between mannose-binding lectin and vascular complications in type 1 diabetes,” Diabetes, vol. 53, no. 6, pp. 1570–1576, 2004. View at Publisher · View at Google Scholar
  7. J. Østergaard, T. K. Hansen, S. Thiel, and A. Flyvbjerg, “Complement activation and diabetic vascular complications,” Clinica Chimica Acta, vol. 361, no. 1-2, pp. 10–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. K. Hansen, “Mannose-binding lectin (MBL) and vascular complications in diabetes,” Hormone and Metabolic Research, vol. 37, Supplement 1, pp. 95–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Flyvbjerg, “Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily,” Nature Reviews Endocrinology, vol. 6, no. 2, pp. 94–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. E. Degn and S. Thiel, “Humoral pattern recognition and the complement system,” Scandinavian Journal of Immunology, vol. 78, no. 2, pp. 181–193, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. V. Sarma and P. A. Ward, “The complement system,” Cell and Tissue Research, vol. 343, no. 1, pp. 227–235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. L. Henriksen, J. Brandt, J. P. Andrieu et al., “Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system,” The Journal of Immunology, vol. 191, no. 12, pp. 6117–6127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Aronson, “Hyperglycemia and the pathobiology of diabetic complications,” Advances in Cardiology, vol. 45, pp. 1–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Esper, J. O. Vilariño, R. A. Machado, and A. Paragano, “Endothelial dysfunction in normal and abnormal glucose metabolism,” Advances in Cardiology, vol. 45, pp. 17–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Del Turco and G. Basta, “An update on advanced glycation endproducts and atherosclerosis,” BioFactors, vol. 38, no. 4, pp. 266–274, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. T. K. Hansen, S. Thiel, S. T. Knudsen et al., “Elevated levels of mannan-binding lectin in patients with type 1 diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 10, pp. 4857–4861, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Østergaard, M. Bjerre, F. Dagnæs‐Hansen, T. K. Hansen, S. Thiel, and A. Flyvbjerg, “Diabetes-induced changes in mannan-binding lectin levels and complement activation in a mouse model of type 1 diabetes,” Scandinavian Journal of Immunology, vol. 77, no. 3, pp. 187–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Østergaard, S. Thiel, M. Gadjeva, T. K. Hansen, R. Rasch, and A. Flyvbjerg, “Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice,” Diabetologia, vol. 50, no. 7, pp. 1541–1549, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Axelgaard, J. A. Østergaard, S. Thiel, and T. K. Hansen, “Diabetes is associated with increased autoreactivity of mannan-binding lectin,” Journal of Diabetes Research, vol. 2017, Article ID 6368780, 12 pages, 2017. View at Publisher · View at Google Scholar
  20. J. A. Østergaard, M. M. Ruseva, T. H. Malik et al., “Increased autoreactivity of the complement-activating molecule mannan-binding lectin in a type 1 diabetes model,” Journal of Diabetes Research, vol. 2016, Article ID 1825738, 7 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ruseva, M. Kolev, F. Dagnaes‐Hansen et al., “Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment,” Immunology, vol. 127, no. 2, pp. 279–288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. G. H. Tesch and T. J. Allen, “Rodent models of streptozotocin-induced diabetic nephropathy,” Nephrology (Carlton), vol. 12, no. 3, pp. 261–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. V. Petersen, S. Thiel, L. Jensen, R. Steffensen, and J. C. Jensenius, “An assay for the mannan-binding lectin pathway of complement activation,” Journal of Immunological Methods, vol. 257, no. 1-2, pp. 107–116, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. T. H. Malik, A. Cortini, D. Carassiti, J. J. Boyle, D. O. Haskard, and M. Botto, “The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice,” Circulation, vol. 122, no. 19, pp. 1948–1956, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Hovind, T. K. Hansen, L. Tarnow et al., “Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study,” Diabetes, vol. 54, no. 5, pp. 1523–1527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. C. D. Collard, C. D. Collard, A. Väkevä et al., “Complement activation after oxidative stress: role of the lectin complement pathway,” The American Journal of Pathology, vol. 156, no. 5, pp. 1549–1556, 2000. View at Publisher · View at Google Scholar
  27. G. L. Weinhouse, P. N. Belloni, and H. W. Farber, “Effect of hypoxia on endothelial cell surface glycoprotein expression: modulation of glycoprotein IIIa and other specific surface glycoproteins,” Experimental Cell Research, vol. 208, no. 2, pp. 465–478, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Pradhan, P. Surve, and K. Ghosh, “Mannose binding lectin (MBL) in autoimmunity and its role in systemic lupus erythematosus (SLE),” JAPI, vol. 58, pp. 688–690, 2010. View at Google Scholar
  29. M. Boniotto, L. Braida, V. Baldas et al., “Evidence of a correlation between mannose binding lectin and celiac disease: a model for other autoimmune diseases,” Journal of Molecular Medicine, vol. 83, no. 4, pp. 308–315, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Tsutsumi, R. Takahashi, and T. Sumida, “Mannose binding lectin: genetics and autoimmune disease,” Autoimmunity Reviews, vol. 4, no. 6, pp. 364–372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu, “Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies,” Cardiovascular Research, vol. 78, no. 2, pp. 265–273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. C. H. Leo, A. Joshi, and O. L. Woodman, “Short-term type 1 diabetes alters the mechanism of endothelium-dependent relaxation in the rat carotid artery,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 299, no. 2, pp. H502–H511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. L. Stahl, W. R. Reenstra, and G. Frendl, “Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex,” Circulation Research, vol. 76, no. 4, pp. 575–583, 1995. View at Publisher · View at Google Scholar
  34. V. I. Pavlov, L. R. La Bonte, W. M. Baldwin, M. M. Markiewski, J. D. Lambris, and G. L. Stahl, “Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications,” The American Journal of Pathology, vol. 180, no. 1, pp. 104–112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Fortpied, D. Vertommen, and E. Van Schaftingen, “Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 4, pp. 254–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. W.-X. Fan, “Activation of the lectin complement pathway on human renal glomerular endothelial cells triggered by high glucose and mannose-binding lectin,” African Journal of Biotechnology, vol. 10, no. 80, pp. 18539–18549, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. N. Busche, M. C. Walsh, M. M. ME, B. J. Guikema, and G. L. Stahl, “Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes,” Diabetologia, vol. 51, no. 8, pp. 1544–1551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Harman, P. V. Kaye, R. Harris, A. Suzuki, A. Gazis, and G. P. Aithal, “Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes,” Hepatology, vol. 60, no. 1, pp. 158–168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. G. N. Levinthal and A. S. Tavill, “Liver disease and diabetes mellitus,” Clinical Diabetes, vol. 17, no. 2, p. 73, 1999. View at Google Scholar
  40. Z. Makita, S. Radoff, E. J. Rayfield et al., “Advanced glycosylation end products in patients with diabetic nephropathy,” The New England Journal of Medicine, vol. 325, no. 12, pp. 836–842, 1991. View at Publisher · View at Google Scholar
  41. H. Hyogo and S. I. Yamagishi, “Advanced glycation end products (AGEs) and their involvement in liver disease,” Current Pharmaceutical Design, vol. 14, no. 10, pp. 969–972, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A. M. Wessels, S. A. Rombouts, P. L. Remijnse et al., “Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume,” Diabetologia, vol. 50, no. 8, pp. 1763–1769, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. G. J. Biessels, A. C. Kappelle, B. Bravenboer, D. W. Erkelens, and W. H. Gispen, “Cerebral function in diabetes mellitus,” Diabetologia, vol. 37, no. 7, pp. 643–650, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. C. T. Kodl, D. T. Franc, J. P. Rao et al., “Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function,” Diabetes, vol. 57, no. 11, pp. 3083–3089, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. C. Ferguson, A. Blane, P. Perros et al., “Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia,” Diabetes, vol. 52, no. 1, pp. 149–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. D. Goldman, “Lung dysfunction in diabetes,” Diabetes Care, vol. 26, no. 6, pp. 1915–1918, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Hamdy, M. Amin, and A. Rashad, “Pulmonary function changes in diabetic lung,” Egyptian Journal of Chest Diseases and Tuberculosis, vol. 62, no. 3, pp. 513–517, 2013. View at Publisher · View at Google Scholar
  48. G. L. Kinney, J. L. Black-Shinn, E. S. Wan et al., “Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease,” Diabetes Care, vol. 37, no. 2, pp. 389–395, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, no. 1, pp. 137–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Strojek, D. Ziora, J. W. Sroczynski, and K. Oklek, “Pulmonary complications of type 1 (insulin-dependent) diabetic patients,” Diabetologia, vol. 35, no. 12, pp. 1173–1176, 1992. View at Publisher · View at Google Scholar · View at Scopus